Andrés Redondo - Publications, H-index & Citations

Andrés Redondo

hospital universitario la paz

45H指数

381论文数

1.5W被引数

收录论文 87

发表时间

Assessing platinum response in first-line advanced ovarian cancer: Clinical implications and future directions 评估铂类反应在一线晚期卵巢癌中的临床意义及未来方向

International Journal of Gynecological Cancer

IF4.7

2026-04-03

PREAI

Maria-Pilar Barretina-Ginesta; Andrés Redondo; Alfonso Cortés-Salgado; Ainhoa Madariaga; Belén Pérez-Mies; Lidia Sancho; Laia Valls-Masot; Marina Domínguez; Antonio González-Martín

The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas CTNNB1突变低级别早期子宫内膜癌的蛋白质组学景观

Cells 2025, Vol. 14, Page 1676

IF5.2

2025-10-27

OAAI

Alvaro Lopez-Janeiro; Emilia Brizzi; Ignacio Ruz-Caracuel; Raluca Alexandru; Carlos de Andrea; Alberto Berjón; Laura Yebenes; Marta Mendiola; Victoria Heredia-Soto; Ana Montero-Calle; Rodrigo Barderas; Vivian de los Rios; Andrés Redondo; Alberto Pelaez-Garcia; David Hardisson

Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines 软组织肉瘤的诊断与治疗：西班牙肉瘤研究组（GEIS）指南

Cancers 2025, Vol. 17, Page 3158

IF4.4

2025-09-29

OAAI

Maria Angeles Vaz-Salgado; Claudia Valverde-Morales; Rosa Alvarez; Jose Manuel Asencio; Erica Collado; Enrique de Alava; Roberto Diaz Beveridge; M. Carmen Gómez-Mateo; Isidro Gracia Alegria; Gloria Marquina; Javier Martin Broto; Javier Martínez-Trufero; José Antonio Narváez García; Andres Redondo; Ana Sebio; Ramona Verges; Joan Maria Viñals; Xavier García del Muro

Dostarlimab and niraparib in primary advanced ovarian cancer 多斯塔利姆单抗和尼拉帕利在原发性晚期卵巢癌中的应用

Annals of Oncology

IF65.4

2025-06-02

OAAI

A.-C. Hardy-Bessard; E. Pujade-Lauraine; R.G. Moore; F. Montestruc; A. Redondo; M.R. Mirza; D. Cibula; T.-E. Ciuleanu; L. Gilbert; R. Eitan; F. Zagouri; S. Pignata; R. Glasspool; J. Pfisterer; R. Phaëton; C.K. Anderson; M. Rodrigues; L. Gaba; E. Bakirtzi; J.M. Fauci; E. Kalbacher; F.B. Musa; S. Gorman; L.R. Duska; L. Gladieff; P. Braly; F. Joly; J. Thomes Pepin; I. Ray-Coquard; K.N. Moore

An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study)一项关于DOstarlimab在复发性或晚期DNA错配修复缺陷/微卫星高度不稳定子宫内膜癌患者中的前瞻性、真实世界、多中心研究（GEICO 120-R/DORA研究）

International Journal of Gynecological Cancer

IF4.7

2025-04-26

PREAI

Alejandro Gallego; Ainhoa Madariaga; Purificación Estévez-García; Facundo Albertí; Anna Carbó; Isabel Palacio; Cristina Churruca; Fernando Gálvez; María Eugenia Ortega; Paola Murata; Aránzazu Manzano; María Masvidal; Cristina Martín-Lorente; Blanca Hernando; Inmaculada Lozano; Juan F. Cueva; David García-Illescas; Ester Gost; Marta Mendiola; Andrés Redondo

ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety ENGOT-OV16/NOVA试验中 niraparib 治疗复发卵巢癌的生存率与长期安全性

gynecologic oncology

IF4.1

2025-04-01

PREAI

Matulonis, Ursula A.; Herrstedt, Jorn; Oza, Amit; Mahner, Sven; Redondo, Andres; Berton, Dominique; Berek, Jonathan S.; Haslund, Charlotte A.; Marme, Frederik; Gonzalez-Martin, Antonio; Becourt, Stephanie; Tinker, Anna, V; Ledermann, Jonathan A.; Benigno, Benedict; Lindahl, Gabriel; Colombo, Nicoletta; Malinowska, Izabela A.; Liu, Wenlei; Bains, Manjinder; Monk, Bradley J.; Mirza, Mansoor R.

Palbociclib plus letrozole in estrogen receptor-positive advanced/ recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial 帕博西利联合来曲唑在雌激素受体阳性晚期/复发性子宫内膜癌中的应用：双盲安慰剂对照随机II期ENGOT-EN3/PALEO试验

gynecologic oncology

IF4.1

2025-01-01

OAAI

Mirza, Mansoor R.; Bjorge, Line; Marme, Frederik; Christense, Rene DePont; Gil-Martin, Marta; Auranen, Annika; Ataseven, Beyhan; Rubio, Maria Jesus; Salutari, Vanda; Luczak, Adam A.; Runnebaum, Ingo B.; Redondo, Andres; Lindemann, Kristina; Trillsc, Fabian; Ginesta, M. Pilar Barretina; Roed, Henrik; Kurtz, Jean-Emmanuel; Petersson, Karen S.; Nyvang, Gitte-Bettina; Sehouli, Jalid

Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial

CANCER

IF5.1

2024-11-14

PREAI

Palmerini, Emanuela; Lopez Pousa, Antonio; Grignani, Giovanni; Redondo, Andres; Hindi, Nadia; Provenzano, Salvatore; Sebio, Ana; Martin, Jose Antonio Lopez; Valverde, Claudia; Trufero, Javier Martinez; Gutierrez, Antonio; de Alava, Enrique; Gomez, Maria Pilar Aparisi; D'Ambrosio, Lorenzo; Collini, Paola; Bazzocchi, Alberto; Moura, David S.; Ibrahim, Toni; Stacchiotti, Silvia; Broto, Javier Martin

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ ENGOT-OV26/GOG-3012 trial 新诊断晚期卵巢癌患者的尼拉帕尼一线维持治疗: PRIMA/ ENGOT-OV26/GOG-3012试验的最终总生存期结果

ANNALS OF ONCOLOGY

IF65.4

2024-11-01

OAAI

Monk, B. J.; Barretina-Ginesta, M. P.; Pothuri, B.; Vergote, I.; Graybill, W.; Mirza, M. R.; Mccormicky, C. C.; Lorusso, D.; Moore, R. G.; Freyer, G.; O'Cearbhaill, R. E.; Heitz, F.; O'Malley, D. M.; Redondo, A.; Shahin, M. S.; Vulsteke, C.; Bradley, W. H.; Haslund, C. A.; Chase, D. M.; Pisano, C.; Holman, L. L.; Perez, M. J. Rubio; Disilvestro, P.; Gaba, L.; Herzog, T. J.; Bruchim, I.; Compton, N.; Shtessel, L.; Malinowska, I. A.; Gonzalez-Martin, A.

Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012 新诊断的晚期卵巢癌(aOC)患者(pts)接受尼拉帕利(nir)一线(1L)维持治疗后的最终总生存期(OS)结果：来自PRIMA/ENGOT-OV26/GOG-3012研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Gonzalez-Martin, A.; Pothuri, B.; Barretina Ginesta, M. P.; Graybill, W. S.; Vergote, I. B.; McCormick, C.; Mirza, M. R.; Moore, R. G.; Lorusso, D.; O'Cearbhaill, R. E.; Freyer, G.; O'Malley, D. M.; Heitz, F.; Shahin, M. S.; Bruchim, I.; Bradley, W. H.; Compton, N.; Malinowska, I.; Redondo, A.; Monk, B. J.

IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study IMMUNOSARC II主试验（舒尼替尼和纳武利尤单抗的II期）：透明细胞肉瘤（CCS）队列的结果：一项GEIS、ISG和UCL研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Martin-Broto, J.; Palmerini, E.; Valverde Morales, C. M.; Sebio Garcia, A.; Redondo, A.; Stacchiotti, S.; Strauss, S.; Grignani, G.; Aliberti, S.; Diaz Beveridge, R. P.; Gonzalez Billalabeitia, E.; Cruz Jurado, J.; Gutierrez Garcia, A. M.; Ledesma, P.; Da Silva Moura, D.; Hindi Muniz, N.

Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-09-01

PREAI

Carrillo-Garcia, Jaime; Hindi, Nadia; Conceicao, Magda; Sala, Maria Angeles; Ugalde, Aitziber; Lopez-Pousa, Antonio; Bague, Silvia; Sevilla, Isabel; Vicioso, Luis; Ramos, Rafael; Martinez-Trufero, Javier; Mateo, Ma Carmen Gomez; Cruz, Josefina; Hernandez-Leon, Carmen Nieves; Redondo, Andres; Mendiola, Marta; Garcia, Jeronimo Martinez; Hernandez, Jose Emilio; Alvarez, Rosa; Agra, Carolina; de Juan-Ferre, Ana; Valverde, Claudia; Cano, Juana Maria; de Sande, Luis Miguel; Perez-Fidalgo, Jose A.; Lavernia, Javier; Marcilla, David; Gutierrez, Antonio; Moura, David S.; Martin-Broto, Javier

Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study 影响软组织肉瘤患者协会意识的因素：一项多中心横断面研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Mascaro Baselga, P.; Villacampa, G.; Navarro Garces, V.; Sebio Garcia, A.; Alvarez, R. M.; Sala Gonzalez, M. A.; Marquina Ospina, G.; Martinez Trufero, J.; Cano, J. M.; Redondo, A.; Molina Diaz, A.; Vega Cano, K. S.; Salva de Torres, C.; Yaringano Cerna, J. G.; Martinez-Albaladejo, P.; de Torner Vidal, A.; Cicala, C. M.; Tabernero, J.; Valverde Morales, C. M.; Serrano, C.

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer mirvetuximab soravtansine联合贝伐单抗与贝伐单抗在fra-高铂敏感性卵巢癌中的维持治疗

FUTURE ONCOLOGY

IF2.6

2024-07-31

OAAI

O'Malley, David M.; Myers, Tashanna; Wimberger, Pauline; Gorp, Toon Van; Redondo, Andres; Cibula, David; Nicum, Shibani; Rodrigues, Manuel; Backes, Floor J.; Barlin, Joyce N.; Lewin, Sharyn N.; Lim, Peter; Pothuri, Bhavana; Diver, Elisabeth; Banerjee, Susana; Lorusso, Domenica

PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

BRITISH JOURNAL OF CANCER

IF6.8

2024-07-06

OAAI

Kristeleit, Rebecca; Leary, Alexandra; Oaknin, Ana; Redondo, Andres; George, Angela; Chui, Stephen; Seiller, Aicha; Liste-Hermoso, Mario; Willis, Jenna; Shemesh, Colby S.; Xiao, Jim; Lin, Kevin K.; Molinero, Luciana; Guan, Yinghui; Ray-Coquard, Isabelle; Mileshkin, Linda

Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2024-04-01

OAAI

Mendiola, Marta; Saarela, Jani; Escudero, Francisco Javier; Heredia-Soto, Victoria; Potdar, Swapnil; Rodriguez-Marrero, Silvia; Miguel, Maria; Pozo-Kreilinger, Jose Juan; Berjon, Alberto; Ortiz-Cruz, Eduardo; Feliu, Jaime; Redondo, Andres

Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary 随访3.5年时的无进展生存期和安全性: 对新诊断卵巢癌患者进行尼拉帕尼维持治疗的3期PRIMA/ENGOT-OV26/GOG-3012随机试验的结果-简明语言总结

FUTURE ONCOLOGY

IF2.6

2024-03-19

OAAI

Gonzalez-Martin, Antonio; Pothuri, Bhavana; Vergote, Ignace; Graybill, Whitney; Lorusso, Domenica; McCormick, Colleen C.; Freyer, Gilles; Backes, Floor; Heitz, Florian; Redondo, Andres; Moore, Richard G.; Vulsteke, Christof; O'Cearbhaill, Roisin E.; Malinowska, Izabela A.; Shtessel, Luda; Compton, Natalie; Mirza, Mansoor R.; Monk, Bradley J.

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial 先前接受PARP抑制剂 (OReO/ ENGOT-ov38) 治疗的铂敏感复发性卵巢癌患者的维持olaparib再激发: IIIb期试验

ANNALS OF ONCOLOGY

IF65.4

2023-12-01

OAAI

Pujade-Lauraine, E.; Selle, F.; Scambia, G.; Asselain, B.; Marme, F.; Lindemann, K.; Colombo, N.; Madryl, R.; Glasspool, R.; Vergote, I.; Korach, J.; Lheureux, S.; Dubot, C.; Oaknin, A.; Zamagni, C.; Heitz, F.; Gladieff, L.; Rubio-Perez, M. J.; Scollo, P.; Blakeley, C.; Shaw, B.; Ray-Coquard, I; Redondo, A.

Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry

ESMO OPEN

IF8.3

2023-12-01

OAAI

Hindi, N.; Razak, A.; Rosembaum, E.; Jonczak, E.; Hamacher, R.; Rutkowski, P.; Bhadri, V. A.; Skryd, A.; Brahmi, M.; Alshibany, A.; Jagodzinska-Mucha, P.; Bauer, S.; Connolly, E.; Gelderblom, H.; Boye, K.; Henon, C.; Bae, S.; Bogefors, K.; Vincenzi, B.; Martinez-Trufero, J.; Lopez-Martin, J. A.; Redondo, A.; Valverde, C.; Blay, J. -Y.; Moura, D. S.; Gutierrez, A.; Tap, W.; Martin-Broto, J.

Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients: Results from the SYNERGIAS study - A Spanish group for research in sarcoma (GEIS) phase II study

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Martin-Broto, J.; Kopeckova, K.; Azinovic, I.; Cruz Jurado, J.; Guzman, L.; Alvarez, R. M.; Casado Herraez, A.; Valverde Morales, C. M.; Sanchez, A. Redondo; Teres Lleida, R.; Alvarez Gonzalez, A.; Dolado, M. C.; Doval, A.; Belinchon, B.; Merino, J. A.; Mendez, R.; Ledesma, P.; Gutierrez, A.; Da Silva Moura, D.; Hindi Muniz, N.

研究方向